Cargando…

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach

AIM: To assess the efficacy and tolerance of programmed death-1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors and the impact of a standardised management-based protocol in a real-world setting. PATIENTS AND METHODS: Data from patients who had received anti-PD-(L)1 were collected from our pharmacy databa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grimaud, Fabien, Penaranda, Guillaume, Stavris, Chloé, Retornaz, Frédérique, Brunel, Véronique, Cailleres, Sylvie, Pegliasco, Hervé, Le Treut, Jacques, Grisoni, Vincent, Coquet, Emilie, Chiche, Laurent, Rognon, Amélie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256379/ https://www.ncbi.nlm.nih.gov/pubmed/34234443 http://dx.doi.org/10.2147/TCRM.S308194

Ejemplares similares

Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results
por: Halfon, Philippe, et al.
Publicado: (2021)

Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study
por: Peretti, Matthieu, et al.
Publicado: (2023)

Long-term neuromuscular consequences of SARS-Cov-2 and their similarities with myalgic encephalomyelitis/chronic fatigue syndrome: results of the retrospective CoLGEM study
por: Retornaz, Frédérique, et al.
Publicado: (2022)

Les anti-CD20 : principal facteur prédictif de réponse vaccinale humorale et cellulaire dans une cohorte de patients atteints de diverses affections dysimmunitaires : une étude prospective en vie réelle
por: Escoda, T., et al.
Publicado: (2023)

Séquelles physiques et psychiques 3–6 mois après la COVID-19 : premiers résultats de la cohorte prospective ALCOVID
por: Chiche, L., et al.
Publicado: (2021)

Anti-spike protein to determine SARS-CoV-2 antibody levels: Is there a specific threshold conferring protection in immunocompromised patients?
por: Halfon, Philippe, et al.
Publicado: (2023)

Une fixation pulmonaire au TEP-scan
por: Cohen, F., et al.
Publicado: (2021)

An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients
por: Halfon, Philippe, et al.
Publicado: (2021)

Conséquences neuromusculaires à long terme de la COVID-19 : analogies avec l’encéphalomyélite myalgique/syndrome de fatigue chronique
por: Retornaz, F., et al.
Publicado: (2022)

Altered muscle membrane potential and redox status differentiates two subgroups of patients with chronic fatigue syndrome
por: Jammes, Yves, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Human Stool Preservation Impacts Taxonomic Profiles in 16S Metagenomics Studies
por: Plauzolles, Anne, et al.
Publicado: (2022)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions
por: Moret, Frederique M, et al.
Publicado: (2014)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
por: Foy, Jean-Philippe, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo
por: Wang, Yan, et al.
Publicado: (2022)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling
por: Carter, Rachel, et al.
Publicado: (2023)

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
por: Dosset, Magalie, et al.
Publicado: (2018)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ah10u0f2ff2r26mej85h7t0mvd